RudaCure a été sélectionnée pour le 2021 Bio-Medical Technology Development Project (Principal Investigator: Yuseung Ha) for its expansion mondiale initiative. Grâce à cela project, l'entreprise will receive support until July of the same year for foundational research on establishing an overseas subsidiary and business collaboration for the U.S. essais cliniques of the ophtalmique eye drop RCI001.
In the project evaluation, l'entreprise a été reconnue pour its excellent R&D and commercialization progress and analysis, ainsi que its clear global startup goals. L'entreprise was selected by recognizing the marketability and future potential of RCI001 in a world where no fundamental treatment drug for sécheresse oculaire actuellement exists.
This project will select 5 companies through a first-round evaluation and provide annual support of KRW 300 million per year for 3 years for expansion mondiale activities.